Blood Drugs Flashcards
MOA and clinical uses for aminocaproic acid
MOA: lysine analogue that binds to and inhibits plasmin (to inhibit fibrinolysis)
Clinical uses: various bleeding disorders
MOA and clinical uses for alteplase
MOA: converts plasminogen to plasmin –> fibrinolysis
Clinical uses: MI, PE, ischemic stroke
MOA and clinical uses for cyclosporine
MOA: inhibits calcineurin (involved in T cell proliferation)
Clinical uses: after marrow transplant to prevent GVHD, idiopathic aplastic anemia
MOA and clinical uses for dabigatran
MOA: direct thrombin (factor II) inhibitior
Clinical uses: stroke prevention in a-fib patients, DVT, PE
MOA and clinical uses for desmopressin
MOA: V2 receptor agonist; stimulates vWF release from endothelial cells
Clinical uses: von Willebrand disease, other qualitative platelet disorders
MOA and clinical uses for eltrombopag
MOA: TPO receptor agonist –> stimulates megakaryocytes
Clinical uses: chronic idiopathic thrombocytopenic purpura, idiopathic acquired aplastic anemia
MOA and clinical uses for enoxaparin
MOA: indirect factor Xa inhibitor
Clinical uses: venous thrombosis prophylaxis or treatment of acute coronary syndromes
MOA and clinical uses for epoetin alfa
MOA: EPO receptor agonist
Clinical uses: anemia secondary to cancer, kidney disease, IBD (?)
MOA and clinical uses for filgrastim.
MOA: G-CSF analogue –> more neutrophils
Clinical uses: neutropenia secondary to chemo or bone marrow transplantation
MOA and clinical uses for fondaparinux
MOA: indirect factor Xa inhibitor
Clinical uses: venous thrombosis prophylaxis or treatment of acute coronary syndromes
MOA and clinical uses for hydroxyurea.
MOA: inhibitor of ribonucleotide reductase; somehow stimulates HbF production; also reduces WBC count, which helps sickle cell patients decrease RBC aggregation intravascularly
Clinical uses: sickle cell anemia, myeloproliferative disorders
MOA and clinical uses for imatinib
MOA: tyrosine kinase inhibitor (ABL, Kit, PDGF-R)
Clinical uses: CML, Philadelphia chromosome (+) ALL
MOA and clinical uses for rituximab
MOA: binds to CD20 on B cells –> dead B cells
Clinical uses: idiopathic thrombocytopenic purpura (ITP), CD20-expressing hematopoietic malignancies
MOA and clinical uses for rivaroxaban
MOA: direct factor Xa inhibitor
Clinical uses: stroke prevention in a-fib, DVT, PE
MOA and clinical uses for romiplostim
MOA: TPO receptor agonist
Clinical uses: chronic idiopathic thrombocytopenic purpura
MOA and clinical uses for warfarin
MOA: inhibits vitamin K epoxide reductase –> no factors II, VII, IX, X, proteins C and S
Clinical uses: stroke prevention in a-fib, DVT, PE, mechanical heart valves
Name a way to reverse warfarin-induced bleeding.
Vitamin K infusion
MOA and clinical uses for unfractionated heparin
MOA: indirect factor IIa (thrombin) and factor Xa inhibitor
Clinical uses: venous thrombosis prophylaxis or treatment of acute coronary syndromes.
Toxicity of warfarin
Bleeding
Toxicity of unfractionated heparin
Bleeding, HIT, osteoporosis w/ chronic use
Toxicity of rivaroxaban
Bleeding
Toxicity of rituximab
Neutropenia
Toxicity of imatinib
CHF, GI upset
Toxicity of hydroxyurea
Cytopenias
Toxicity of fondaparinux
Bleeding
Toxicity of filgrastim
Bone pain
Toxicity of epoetin alfa
Hypertension, thrombosis
Toxicity of enoxaparin
Bleeding, thrombocytopenia
Toxicity of dabigatran
Bleeding, GI disturbances
Toxicity of cyclosporine
Hypertension, electrolyte wasting, nephrotoxicity
Toxicity of alteplase
Bleeding, intracranial hemorrhage
Toxicity of aminocaproic acid
Thrombosis